Analyze interleukin-1β, interleukin-6, and tumor necrosis factor-α levels in dry eye and the therapeutic effect of cyclosporine A

Table 1 Inflammatory indexes in the observation and healthy groups

Group	n	IL-6 in pg/mL	TNF-α in ng/L	IL-1β in ng/L
Observation group	124	153.67 ± 4.12	46.34 ± 1.54	42.23 ± 2.12
Healthy group	20	36.34 ± 2.53	12.32 ± 1.34	11.42 ± 1.82
t value	-	13.232	14.232	14.722
P value	-	< 0.05	< 0.05	< 0.05

Data are mean ± standard deviation. IL-1β: Interleukin-1β; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha.

Table 2 Inflammatory indicators in the study and control groups

Group	n	Time	IL-6 in pg/mL	TNF-α in ng/L	IL-1β in ng/L
Control group	62	Before treatment	152.34 ± 3.67	46.35 ± 2.09	42.42 ± 2.21
		Aftertreatment	89.43 ± 4.12a	28.43 ± 1.25a	23.25 ± 2.08a
Study group	62	Before treatment	154.11 ± 4.12	46.32 ± 2.31	42.15 ± 2.18
		After treatment	65.34 ± 3.19a,c	16.57 ± 1.11a,c	18.42 ± 1.84a,c

Data are mean ± standard deviation.

^aP < 0.05 vs before treatment.

^cP < 0.05 vs control group at the same time.

IL-1β: Interleukin-1β; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha.

Table 3 Comparison of Schirmer’s test, tear break-up time and corneal fluorescein staining

Group	n	Time	SIT in mm/5 min	TBUT in s	FL points
Control group	62	Before treatment	6.41 ± 1.32	7.47 ± 1.43	5.18 ± 0.45
		After treatment	9.24 ± 1.97a	7.43 ± 1.65a	2.53 ± 0.35a
Study group	62	Before treatment	6.38 ± 2.14	7.04 ± 1.25	5.14 ± 0.51
		After treatment	12.21 ± 2.41a,c	11.54 ± 1.58a,c	1.25 ± 0.36a,c

Data are mean ± standard deviation.

^aP < 0.05 vs before treatment.

^cP < 0.05 vs control group at the same time.

TBUT: Tear break-up time; FL: Corneal fluorescein staining; SIT: Schirmer’s test.

Table 4 Comparison of subjective symptoms scores

Group	n	Time	Dry eyes	Photophobia	Foreign body sensation	Feeling tired	Redeyes	Burning sensation
Control group	62	Before treatment	3.82 ± 0.34	1.69 ± 0.24	1.75 ± 0.43	1.93 ± 0.21	1.67 ± 0.21	1.26 ± 0.25
		After treatment	2.18 ± 0.32a	0.77 ± 0.23a	0.72 ± 0.31a	0.89 ± 0.17a	0.67 ± 0.16a	0.56 ± 0.15a
Study group	62	Before treatment	3.97 ± 0.42	1.71 ± 0.32	1.78 ± 0.25	1.91 ± 0.35	1.64 ± 0.32	1.27 ± 0.23
		After treatment	1.54 ± 0.41a,c	0.53 ± 0.14a,c	0.51 ± 0.32a,c	0.70 ± 0.34a,c	0.53 ± 0.15a,c	0.46 ± 0.21a,c

Data are mean ± standard deviation.

^aP < 0.05 for comparison of before and after treatment in the same group.

^cP < 0.05 for comparison to the control group and study group at the same time.

Table 5 NEI-VFQ-25 score detection

Group	n	Time	Mobility barriers	Visual impairment	Health conditions
Control group	62	Before treatment	80.34 ± 3.12	85.12 ± 4.35	55.23 ± 3.54
		After treatment	92.12 ± 3.52a	90.23 ± 5.12a	61.23 ± 4.12a
Study group	62	Before treatment	80.34 ± 4.11	85.45 ± 3.25	56.23 ± 4.12
		After treatment	99.67 ± 3.64a,c	99.34 ± 3.25a,c	68.84 ± 3.81a,c

Data are mean ± standard deviation.

^aP < 0.05 for comparison of before and after treatment in the same group.

^cP < 0.05 for comparison to the control group and study group at the same time.